Dermatitis herpetiformis: specific manifestation of celiac disease

Simple item page
dc.creatorCorrea Parra, Laura
dc.creatorVilla Saldarriaga , Maria Paulina
dc.creatorForero Saldarriaga, Santiago
dc.date2021-10-29
dc.date.accessioned2024-09-12T00:54:03Z
dc.date.available2024-09-12T00:54:03Z
dc.descriptionCeliac disease is a systemic disorder with an autoimmune basis, secondary to continuous exposure to gluten in people with genetic susceptibility, which leads to the development of specific antibodies mainly affecting the small intestine with subsequent enteropathy. The clinical manifestations include digestive symptoms and extra intestinal manifestations. In this last group, the dermatological manifestations stand out, specifically dermatitis herpetiformis, which is considered specific to Celiac disease. It presents clinically as a pruritic papulovesicular rash. The diagnosis is based on a skin biopsy with direct immunofluorescence and the presence of anti-tissue transglutaminase 2 antibodies, only in specific cases it should be complemented with other studies. Treatment is based on a gluten-free diet, which improves symptoms, controls and prevents complications of Celiac disease, such as digestive neoplasms and the development of other autoimmune diseases.en-US
dc.descriptionLa enfermedad celíaca es un trastorno sistémico con base autoinmune, secundario a la exposición continua al gluten en personas con susceptibilidad genética, que lleva a desarrollo de anticuerpos específicos, afectando principalmente el intestino delgado con la subsecuente enteropatía. Las manifestaciones clínicas incluyen síntomas digestivos y manifestaciones extra intestinales. En este último grupo se destacan las manifestaciones dermatológicas, específicamente la dermatitis herpetiforme, la cual es considerada específica de la enfermedad celíaca. Clínicamente, se presenta como un exantema papulovesicular pruriginoso. El diagnóstico se basa en la biopsia de piel con inmunofluorescencia directa y la presencia de anticuerpos anti-transglutaminasa tisular 2 y solo en casos específicos se debe complementar con otros estudios. El tratamiento se basa en dieta libre de gluten, que mejora la sintomatología, controla y previene las complicaciones de la enfermedad celíaca, como las neoplasias digestivas y el desarrollo de otras enfermedades autoinmunes.es-ES
dc.formatapplication/pdf
dc.identifierhttps://revistas.ces.edu.co/index.php/medicina/article/view/6352
dc.identifier.urihttps://ciencianacional.co/handle/123456789/208151
dc.journalCES Medicina
dc.languagespa
dc.publisherUniversidad CESes-ES
dc.relationhttps://revistas.ces.edu.co/index.php/medicina/article/view/6352/3504
dc.relation/*ref*/Rubin JE, Crowe SE. Celiac Disease. Ann Intern Med. 2020;172(1): ITC1-16. DOI: 10.7326/AITC202001070
dc.relation/*ref*/Bureš J. History of celiac disease. Vnitr Lek. 2018;64(6):600-1. URL: https://pubmed.ncbi.nlm.nih.gov/30223657/
dc.relation/*ref*/Yu XB, Uhde M, Green PH, Alaedini A. Autoantibodies in the Extraintestinal Manifestations of Celiac Disease. Nutrients. 2018;10(8): E1123. DOI: 10.3390/nu10081123
dc.relation/*ref*/Parra-Medina R, Molano-Gonzalez N, Rojas-Villarraga A, Agmon-Levin N, Arango M-T, Shoenfeld Y, et al. Prevalence of Celiac Disease in Latin America: A Systematic Review and Meta-Regression. PLOS ONE. 2015;10(5): e0124040. DOI: 10.1371/journal.pone.0124040
dc.relation/*ref*/Therrien A, Kelly CP, Silvester JA. Celiac Disease: Extraintestinal Manifestations and Associated Conditions. J Clin Gastroenterol. 2020;54(1): 8-21. DOI: 10.1097/MCG.0000000000001267
dc.relation/*ref*/Abenavoli L, Dastoli S, Bennardo L, Boccuto L, Passante M, Silvestri M, et al. The Skin in Celiac Disease Patients: The Other Side of the Coin. Medicina (Mex). 2019;55(9): 578. DOI: 10.3390/medicina55090578
dc.relation/*ref*/Leffler DA, Green PHR, Fasano A. Extraintestinal manifestations of coeliac disease. Nat Rev Gastroenterol Hepatol. 2015;12(10): 561-71. DOI: 10.1038/nrgastro.2015.131
dc.relation/*ref*/Lebwohl B, Sanders DS, Green PHR. Coeliac disease. Lancet Lond Engl. 2018;391(10115): 70-81.
dc.relation/*ref*/Antiga E, Maglie R, Quintarelli L, Verdelli A, Bonciani D, Bonciolini V, et al. Dermatitis Herpetiformis: Novel Perspectives. Front Immunol. 2019;10: 1290. DOI: 10.3389/fimmu.2019.01290
dc.relation/*ref*/Salmi TT. Dermatitis herpetiformis. Clin Exp Dermatol. 2019;44(7): 728-31. DOI: 10.1111/ced.13992
dc.relation/*ref*/Sanjinés DL. Dermatitis herpetiforme como carta de presentación de la enfermedad celíaca. Rev Urug Med Interna. 2016;7. URL: http://www.scielo.edu.uy/pdf/rumi/v1n1/v1n1a03.pdf
dc.relation/*ref*/J. FM, P. RQ. Enfermedad celiaca: Revisión. Rev Médica Clínica Las Condes. 2015;26(5): 613-27.
dc.relation/*ref*/Rojas-Vargas C. Enfermedad celíaca: una enfermedad autoinmune. Rev Médica Sinerg. 2021;6: 11. DOI: 10.1016/j.rmclc.2015.09.007
dc.relation/*ref*/Jericho H, Sansotta N, Guandalini S. Extraintestinal Manifestations of Celiac Disease: Effectiveness of the Gluten-Free Diet. J Pediatr Gastroenterol Nutr. 2017;65(1):75-9. DOI: 10.1097/MPG.0000000000001420
dc.relation/*ref*/Muddasani S, Rusk AM, Baquerizo Nole KL. Gluten and skin disease beyond dermatitis herpetiformis: a review. Int J Dermatol. 2021;60(3):281-8. DOI: 10.1111/ijd.15098
dc.relation/*ref*/Salmi TT, Hervonen K, Kautiainen H, Collin P, Reunala T. Prevalence and incidence of dermatitis herpetiformis: a 40-year prospective study from Finland. Br J Dermatol. 2011;165(2): 354-9. DOI: 10.1111/j.1365-2133.2011.10385.x
dc.relation/*ref*/Mansikka E, Hervonen K, Kaukinen K, Collin P, Huhtala H, Reunala T, et al. Prognosis of Dermatitis Herpetiformis Patients with and without Villous Atrophy at Diagnosis. Nutrients. 2018;10(5): E641. DOI: 10.3390/nu10050641
dc.relation/*ref*/Lindfors K, Ciacci C, Kurppa K, Lundin KEA, Makharia GK, Mearin ML, et al. Coeliac disease. Nat Rev Dis Primer. 2019;5(1): 3.
dc.relation/*ref*/Leffler DA, Schuppan D. Update on serologic testing in celiac disease. Am J Gastroenterol. 2010;105(12):2520-4.
dc.relation/*ref*/Pallav K, Kabbani T, Tariq S, Vanga R, Kelly CP, Leffler DA. Clinical Utility of Celiac Disease-Associated HLA Testing. Dig Dis Sci. 2014;59(9): 2199-206. DOI: 10.1038/s41572-018-0054-z
dc.relation/*ref*/Ludvigsson JF, Bai JC, Biagi F, Card TR, Ciacci C, Ciclitira PJ, et al. Diagnosis and management of adult coeliac disease: guidelines from the British Society of Gastroenterology. Gut. 2014;63(8): 1210-28. DOI: 10.1136/gutjnl-2013-306578
dc.relation/*ref*/Downey L, Houten R, Murch S, Longson D, Guideline Development Group. Recognition, assessment, and management of coeliac disease: summary of updated NICE guidance. BMJ. 2015;351:h4513.
dc.relation/*ref*/Antiga E, Caproni M. The diagnosis and treatment of dermatitis herpetiformis. Clin Cosmet Investig Dermatol. 2015;8:257-65. DOI: 10.2147/CCID.S69127
dc.relation/*ref*/Rodrigo L, Beteta-Gorriti V, Alvarez N, Gómez de Castro C, de Dios A, Palacios L, et al. Cutaneous and Mucosal Manifestations Associated with Celiac Disease. Nutrients. 2018;10(7):E800. DOI: 10.3390/nu10070800
dc.relation/*ref*/Baptista A, Madanelo S, Morais P. A pruritic vesicular rash. Aust Fam Physician. 2017;46(1):45-7.
dc.relation/*ref*/Syage JA, Green PHR, Khosla C, Adelman DC, Sealey-Voyksner JA, Murray JA. Latiglutenase Treatment for Celiac Disease: Symptom and Quality of Life Improvement for Seropositive Patients on a Gluten-Free Diet. GastroHep. 2019;1(6):293-301. DOI: 10.1002/ygh2.371
dc.relation/*ref*/Ja M, Cp K, Phr G, A M, Tt W, M M, et al. No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease. Gastroenterology. 2021];152(4). URL:https://pubmed.ncbi.nlm.nih.gov/27864127/
dc.relation/*ref*/Zingone F, Abdul Sultan A, Crooks CJ, Tata LJ, Ciacci C, West J. The risk of community-acquired pneumonia among 9803 patients with coeliac disease compared to the general population: a cohort study. Aliment Pharmacol Ther. 2016;44(1):57-67. DOI: 10.1111/apt.13652
dc.relation.institutionUniversidad CES
dc.rightsDerechos de autor 2021 CES Medicinaes-ES
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/4.0es-ES
dc.sourceCES Medicina; Vol. 35 Núm. 3 (2021): CES Medicina ; 272-283es-ES
dc.source2215-9177
dc.source0120-8705
dc.subjectceliac diseaseen-US
dc.subjectskin diseasesen-US
dc.subjectdermatitis herpetiformisen-US
dc.subjectdieten-US
dc.subjectgluten-freeen-US
dc.subjectenfermedad celíacaes-ES
dc.subjectenfermedades de la pieles-ES
dc.subjectdermatitis herpetiformees-ES
dc.subjectdieta sin glutenes-ES
dc.titleDermatitis herpetiformis: specific manifestation of celiac diseaseen-US
dc.titleDermatitis herpetiforme: manifestación específica de la enfermedad celiacaes-ES
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Files

Collections

vol. 35 núm. 3 (2021): ces medicina